Granted Patent
B2
US 12,220,404 · App. 16/932,352 · Granted Feb 11, 2025
Treatment and management of augmentation in restless legs syndrome
Assignee:
East Carolina University
A61K31/428A61K31/381A61K31/40A61K31/48A61K31/485A61K31/5383A61K31/55A61K45/06A61P43/00A61K9/0019A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides methods of treating Restless Legs Syndrome (RLS) including administering to a subject an effective amount of a dopamine D 1 receptor antagonist. Compositions and kits useful for treating RLS are also provided.
Claims (12)
1. A method of treating augmentation associated with restless legs syndrome (RLS) treatment in a subject in need thereof, comprising administering to the subject an effective amount of ecopipam, thereby treating augmentation in the subject.
2. The method of claim 1 , wherein the ecopipam is administered in combination with a D 3 receptor agonist.
3. The method of claim 1 , wherein the method delays the daily onset of RLS symptoms in the subject relative to treatment with a D 3 receptor agonist alone.
4. The method of claim 1 , wherein the method increases the latency to onset of RLS symptoms in the subject when at rest relative to treatment with a D 3 receptor agonist alone.
5. The method of claim 1 , wherein the method reduces the intensity of symptoms in the subject relative to treatment with a D 3 receptor agonist alone.
6. The method of claim 1 , wherein the method reduces expansion of symptoms to upper limbs and trunk of the subject relative to treatment with a D 3 receptor agonist alone.
7. The method of claim 2 , wherein the D 3 receptor agonist is nafadotride, PD 128907, pramipexole, pergolide, rotigotine, or mixtures thereof.
8. The method of claim 7 , wherein the D 3 receptor agonist is pramipexole.
9. A method of restoring responsiveness or decreasing tolerance to a D 3 receptor agonist in a subject in need thereof, comprising activating a D 3 receptor pathway and inhibiting D 1 receptor activity by administering ecopipam to the subject after D 3 receptor-mediated reduction in responsiveness or increased tolerance to a D 3 receptor agonist in the subject, thereby restoring responsiveness or decreasing tolerance to the D 3 receptor agonist.
10. The method of claim 9 , wherein the subject is at risk for or suffers from augmentation.
11. The method of claim 9 , wherein the D 3 receptor agonist is nafadotride, PD 128907, pramipexole, pergolide, rotigotine, or mixtures thereof.
12. The method of claim 11 , wherein the D 3 receptor agonist is pramipexole.
Continuity (3)
Continuation
15753149
Provisional Application
62207225
· Aug 19, 2015
References Cited (122)
US 20090156581A1
· Dillon et al.
· 2009
[cited by applicant]
US 20100168085A1
· Eisenbach-Schwartz et al.
· 2010
[cited by applicant]
US 20110262442A1
· Hamilton et al.
· 2011
[cited by applicant]
WO 2002100350A2
· 2002
[cited by applicant]
WO 2014012063A1
· 2014
[cited by applicant]
Paulus et al. (Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. The Lancet Neurologyvol. 5, Issue 10, Oct. 2006, pp. 878-886).
[cited by examiner]
Ferini-Strambi (Restless legs syndrome augmentation and pramipexole treatment, Sleep Medicine, vol. 3, Supplement, 2002, pp. S23-S25, ISSN 1389-9457).
[cited by examiner]
“Bekhit, M.H. “Opioid-induced hyperalgesia and tolerance” American Journal of Therapeutics, 17(5):498-510 (2010) (Abstract only)”.
[cited by applicant]
“ClinicalTrials.gov “Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years” https://clinicaltrials.gov/ct2/show/study/NCT02102698#wrapper (9 pages) (2014)”.
[cited by applicant]
“Davies S. “Rotigotine for restless legs syndrome” Drugs Today (Barc), 45(9):663-668 (2009) (Abstract only)”.
[cited by applicant]
“Earley, C.J. “Latest guidelines and advances for treatment of restless legs syndrome” The Journal of Clinical Psychiatry, 75(4):e08 (2014) (Abstract only)”.
[cited by applicant]
“Erman, M.K. “Selected sleep disorders: restless legs syndrome and periodic limb movement disorder, sleep apnea syndrome, and narcolepsy” The Psychiatric Clinics of North America, 29(4):947-967; abstract viii-ix (2006) …
[cited by applicant]
“Extended European Search Report corresponding to European Application No. 16837850.3 dated May 22, 2019”.
[cited by applicant]
“Hubble, J.P. “Pre-clinical studies of pramipexole: clinical relevance” European Journal of Neurology, 7(S1):15-20 (2000) (Abstract only)”.
[cited by applicant]
“International Search Report and the Written Opinion of the International Searching Authority corresponding to International Patent Application No. PCT/US2016/047591 (14 pages) (mailed Nov. 30, 2016)”.
[cited by applicant]
“Rascol, O. “Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?” Journal of Neural Transmission Supplementum, 55:33-45 (1999) (Abstract only)”.
[cited by applicant]
“Wei, L. “Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis” Experimental and Molecular Pathology, 90(1):74-78 (2011) (Abstract only)”.
[cited by applicant]
“Winkelmann, J. “Genetics of restless legs syndrome” Current Neurology and Neuroscience Reports, 8(3):211-216 (2008) (Abstract only)”.
[cited by applicant]
Allen , et al., ““A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome” Sleep Medicine, 11(6):512-519 (2010) (Abstract only)”.
[cited by applicant]
Allen , et al., ““Augmentation of the restless legs syndrome with carbidopa/levodopa” Sleep, 19(3):205-213 (1996) (Abstract only)”.
[cited by applicant]
Allen , et al., ““Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance” …
[cited by applicant]
Allouche , et al., ““Opioid receptor desensitization: mechanisms and its link to tolerance” Frontiers in Pharmacology 5(280):1-20 (2014)”.
[cited by applicant]
Baier , et al., ““Circadian variation in restless legs syndrome” Sleep Medicine, 8(6):645-650 (2007) (Abstract only)”.
[cited by applicant]
Barriere , et al., ““The restless legs syndrome” Progress in Neurobiology, 77(3):139-165 (2005) (Abstract only)”.
[cited by applicant]
Bayard , et al., ““Decision-making, Reward-Seeking Behaviors and Dopamine Agonist Therapy in Restless Legs Syndrome” Sleep, 36(10):1501-1507 (2013)”.
[cited by applicant]
Breese , et al., ““Peripheral inflammation selectively increases TRPV1 function in IB4-positive sensory neurons from adult mouse” Pain, 115(1-2):37-49 (2005) (Abstract only)”.
[cited by applicant]
Brewer , et al., ““Dopamine D3 receptor dysfunction prevents anti-nociceptive effects of morphine in the spinal cord” Frontiers in Neural Circuits, 8:62-01-62-10 (2014)”.
[cited by applicant]
Bubenikova-Valesova , et al., ““The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats” International Journal of Neuropsy…
[cited by applicant]
Chahine , et al., ““Restless legs syndrome: a review” CNS Spectrums, 11(7):511-520 (2006) (Abstract only)”.
[cited by applicant]
Clemens , et al., ““Conversion of the Modulatory Actions of Dopamine on Spinal Reflexes from Depression to Facilitation in D3 Receptor Knock-Out Mice” The Journal of Neuroscience, 24(50):11337-11345 (2004)”.
[cited by applicant]
Clemens , et al., ““Opposing modulatory effects of D1- and D2-like receptor activation on a spinal central pattern generator” Journal of Neurophysiology, 107(8):2250-2259 (2012)”.
[cited by applicant]
Clemens , et al., ““Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective” Neurology, 67(1):125-130 (2006)”.
[cited by applicant]
Connor , et al., ““Postmortem and imaging based analyses reveal CNS decreased myelination in restless legs syndrome” Sleep Medicine, 12(6):614-619 (2011)”.
[cited by applicant]
Cote, et al., ““In vitro and in vivo characterization of the agonist-dependent D3 dopamine receptor tolerance property” Neuropharmacology, 79:359-367 (2014) (Abstract only)”.
[cited by applicant]
Cruz-Trujillo, et al., ““D3 dopamine receptors interact with dopamine D1 but not D4 receptors in the GABAergic terminals of the SNr of the rat” Neuropharmacology, 67:370-378 (2013) (Abstract only)”.
[cited by applicant]
Darmopil , et al., ““Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation” Biological Psychiatry, 66(6):603-613 (2009) (Abstract only)”.
[cited by applicant]
Dauvilliers , et al., ““Restless legs syndrome: update on pathogenesis” Current Opinion in Pulmonary Medicine, 19(6):594-600 (2013) (Abstract only)”.
[cited by applicant]
Deandrade , et al., ““Motor restlessness, sleep disturbances, thermal sensory alterations and elevated serum iron levels in Btbd9 mutant mice” Human Molecular Genetics 21(18):3984-3992 (2012)”.
[cited by applicant]
Dinkins , et al., ““Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1”, Sleep Medicine 40:47-52 (2017)”.
[cited by applicant]
Djouhri , et al., ““Spontaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors” The Journal of Neuroscience, 26(4):1281-1292 (2006)”.
[cited by applicant]
Dougherty , et al., ““Properties of mouse spinal lamina | GABAergic interneurons” Journal of Neurophysiology, 94(5):3221-3227 (2005)”.
[cited by applicant]
Drago , et al., ““Altered striatal function in a mutant mouse lacking D1A dopamine receptors” Proc Natl Acad Sci USA, 91(26):12564-12568 (1994)”.
[cited by applicant]
Dziewczapolski , et al., ““Opposite roles of D1 and D5 dopamine receptors in locomotion revealed by selective antisense oligonucleotides” Neuroreport, 9(1):1-5 (1998) (Abstract only)”.
[cited by applicant]
Earley , et al., ““Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease)” Sleep Medicine, 15(11):1288-1301 (2014) (Abstract only)”.
[cited by applicant]
Earley , et al., ““Increased synaptic dopamine in the putamen in restless legs syndrome” Sleep, 36(1):51-57 (2013)”.
[cited by applicant]
England, et al., ““L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children” Sleep Medicine, 12(5):471-477 (2011)”.
[cited by applicant]
Fiorentini , et al., ““Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization” Molecular Pharmacology, 74(1):59-69 (2008)”.
[cited by applicant]
Garcia-Borreguero , et al., ““Algorithms for the diagnosis and treatment of restless legs syndrome in primary care” BMC Neurology, 11:28 (2011)”.
[cited by applicant]
Garcia-Borreguero , et al., ““Augmentation as a treatment complication of restless legs syndrome: concept and management” Movement Disorders, 22(S18):S476-S484 (2007) (Abstract only)”.
[cited by applicant]
Garcia-Borreguero , et al., ““Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus co…
[cited by applicant]
Garcia-Borreguero , et al., ““Dopaminergic augmentation of restless legs syndrome” Sleep Medicine Reviews, 14(5):339-346 (2010) (Abstract only)”.
[cited by applicant]
Garcia-Borreguero , et al., ““Epidemiology of restless legs syndrome: the current status” Sleep Medicine Reviews, 10(3):153-167 (2006) (Abstract only)”.
[cited by applicant]
Garcia-Borreguero , et al., ““Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks” Movemen…
[cited by applicant]
Garcia-Borreguero , et al., ““The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Leg…
[cited by applicant]
Garcia-Borreguero , et al., ““Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study” Neurology, 74(23):1897-1904 (2010)”.
[cited by applicant]
Garcia-Borreguero , et al., ““Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome” Sleep Medicine, 8(5):455-463 (2007) (Abstract only)”.
[cited by applicant]
Gilbert , et al., ““A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome” Clinical Neuropharmacology, 37(1):26-30 (2014) (Abstract only)”.
[cited by applicant]
Gil-Mast , et al., ““An amino acid residue in the second extracellular loop determines the agonist-dependent tolerance property of the human D3 dopamine receptor” ACS Chemical Neuroscience, 4(6):940-951 (2013)”.
[cited by applicant]
Granado , et al., ““D1 but not D4 dopamine receptors are critical for MDMA-induced neurotoxicity in mice” Neurotoxicity Research, 25(1):100-109 (2014)”.
[cited by applicant]
Guitart , et al., ““Functional Selectivity of Allosteric Interactions within G Protein-Coupled Receptor Oligomers: The Dopamine D1-D3 Receptor Heterotetramer” Molecular Pharmacology, 86(4):417-429 (2014)”.
[cited by applicant]
Hall , et al., ““Changes in mood, depression and suicidal ideation after commencing pregabalin for neuropathic pain” Australian Family Physician, 43(10):705-708 (2014)”.
[cited by applicant]
Han , et al., ““Dopaminergic modulation of spinal neuronal excitability” The Journal of Neuroscience, 27(48):13192-13204 (2007)”.
[cited by applicant]
Han , et al., ““Modulation of AMPA currents by D(1)-like but not D(2)-like receptors in spinal motoneurons” Neuroscience, 158(4):1699-1707 (2009)”.
[cited by applicant]
Hogl , et al., ““Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study” Journal of Neurology, 257(2):230-237 (2010)”.
[cited by applicant]
Huang , et al., ““Smad3 medlates cardiac inflammation and fibrosis in angiotensin II-induced hypertensive cardiac remodeling” Hypertension, 55(5):1165-1171 (2010)”.
[cited by applicant]
Iuga , et al., ““ROS initiated oxidation of dopamine under oxidative stress conditions in aqueous and lipidic environments” The Journal of Physical Chemistry B, 115(42):12234-12246 (2011)”.
[cited by applicant]
Johnson , et al., ““The dopamine D3 receptor knockout mouse mimics aging-related changes in autonomic function and cardiac fibrosis” PLoS One, 8(8):e74116 (2013)”.
[cited by applicant]
Keeler , et al., ““Opposing aging-related shift of excitatory dopamine D1 and inhibitory D3 receptor protein expression in striatum and spinal cord” Journal of Neurophysiology, 115:363-369 (2016)”.
[cited by applicant]
Keeler , et al., ““Increased excitability of spinal pain reflexes and altered frequency-dependent modulation in the dopamine D3-receptor knockout mouse” Experimental Neurology, 238(2):273-283 (2012) (Abstract only)”.
[cited by applicant]
Kustermann , et al., ““Depression and attempted suicide under pregabalin therapy” Annals of General Psychiatry, 13(1):37 (2014)”.
[cited by applicant]
Kuzhikandathil , et al., ““Activation of human D3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells” The Journal of Neuroscience, 19(5):1698-1707 (1999)”.
[cited by applicant]
Kuzhikandathil , et al., ““Identification and characterization of novel properties of the human D3 dopamine receptor” Molecular and Cellular Neurosciences, 26(1):144-155 (2004) (Abstract only)”.
[cited by applicant]
Luo , et al., ““The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model” Sleep Medicine, 12(1):41-46 (2010) (Abstract only)”.
[cited by applicant]
Machacek, et al., ““Serotonin 5-HT(2) receptor activation induces a long-lasting amplification of spinal reflex actions in the rat” The Journal of Physiology, 537(Pt 1):201-207 (2001)”.
[cited by applicant]
Mackie , et al., ““Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation” CNS Drugs, 29(5):351-357 (2015)”.
[cited by applicant]
Maggio , et al., ““Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance” Parkinsonism and Related Disorders, 15(Suppl 4):S2-S7 (2009) (Abstract only)”.
[cited by applicant]
Malik, et al., ““The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia” Pharmacology, Biochemistry, and Behavior, 78(4):805-810 (2004) (Abstract only)”.
[cited by applicant]
Manconi , et al., ““First night efficacy of pramipexole in restless legs syndrome and periodic leg movements” Sleep Medicine, 8(5):491-497 (2007) (Abstract only)”.
[cited by applicant]
Manconi , et al., ““Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome” Neurology, 77(2):110-117 (2011)”.
[cited by applicant]
Massad , et al., ““Vitamin B-sensitized photo-oxidation of dopamine” Photochemistry and Photobiology, 84(5):1201-1208 (2008) (Abstract only)”.
[cited by applicant]
Meneely , et al., ““Differential Dopamine D1 and D3 Receptor Modulation and Expression in the Spinal Cord of Two Mouse Models of Restless Legs Syndrome”, Frontiers in Behavioral Neuroscience vol. 12 (2018) 14 pages”.
[cited by applicant]
Missale , et al., ““The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes” Journal of Receptor and Signal Transduction Research, 30(5):347-354 (2010) (Abstract only)”.
[cited by applicant]
Montplaisir , et al., ““Restless legs syndrome improved by pramipexole: a double-blind randomized trial” Neurology, 52(5):938-943 (1999) (Abstract only)”.
[cited by applicant]
Odin , et al., ““Restless legs syndrome” European Journal of Neurology, 9(S3):59-67 (2002) (Abstract only)”.
[cited by applicant]
Oertel , et al., ““Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study” Lancet Neurology, 10(8):710-720 (2011) (Abs…
[cited by applicant]
Oertel , et al., ““Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study” Sleep Medicine, 11(9):848-856 (2010) (Abstract only)”.
[cited by applicant]
Oliveira De Almeida , et al., ““The effects of long-term dopaminergic treatment on locomotor behavior in rats” Sleep Science, 7(4):203-208 (2014)”.
[cited by applicant]
Paulus , et al., ““Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis for augmentation?” Sleep Medicine Reviews, 10(3):185-196 (2006) (Abstract only)”.
[cited by applicant]
Pham , et al., ““Cu(II)-catalyzed oxidation of dopamine in aqueous solutions: mechanism and kinetics” Journal of Inorganic Biochemistry, 137:74-84 (2014) (Abstract only)”.
[cited by applicant]
Phillips , et al., ““Prevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll” Chest, 129(1):76-80 (2006) (Abstract only)”.
[cited by applicant]
Picchietti , et al., ““Restless legs syndrome: prevalence and impact in children and adolescents—the Peds REST study” Pediatrics, 120(2):253-266 (2007) (Abstract only)”.
[cited by applicant]
Salas , et al., ““All the wrong moves: a clinical review of restless legs syndrome, periodic limb movements of sleep and wake, and periodic limb movement disorder” Clinics in Chest Medicine, 31(2):383-395 (2010) (Abstra…
[cited by applicant]
Samir , et al., ““Morphine responsiveness to thermal pain stimuli is aging-associated and mediated by Dopamine D1 and D3 receptor interactions” Neuroscience, 349:87-97 (2017)”.
[cited by applicant]
Scholz, et al., ““Dopamine agonists for restless legs syndrome” The Cochrane Database of Systematic Reviews, (3):CD006009 (2011) (Abstract only)”.
[cited by applicant]
Scholz , et al., ““Levodopa for restless legs syndrome” The Cochrane Database of Systematic Reviews, (2):CD005504 (2011) (Abstract only)”.
[cited by applicant]
Schormair , et al., ““MEIS1 and BTBD9: genetic association with restless leg syndrome in end stage renal disease” Journal of Medical Genetics, 48(7):462-466 (2011)”.
[cited by applicant]
Schormair , et al., ““PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome” Nature Genetics, 40(8):946-948 (2008)”.
[cited by applicant]
Shreckengost , et al., ““Bicuculline-sensitive primary afferent depolarization remains after greatly restricting synaptic transmission in the mammalian spinal cord” The Journal of Neuroscience, 30(15):5283-5288 (2010)”.
[cited by applicant]
Silver , et al., ““A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome” Sleep Medicine, 12(5):440-444 (2011) (Abstract only)”.
[cited by applicant]
Spieler , et al., ““Restless legs syndrome-associated intronic common variant in Meis1 alters enhancer function in the developing telencephalon” Genome Research, 24(4):592-603 (2014)”.
[cited by applicant]
Stefansson , et al., ““A genetic risk factor for periodic limb movements in sleep” The New England Journal of Medicine, 357(7):639-647 (2007)”.
[cited by applicant]
Stiasny-Kolster , et al., ““Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany” Sleep Medicine, 14(6):475-481 (20…
[cited by applicant]
Stiasny-Kolster , et al., ““Low-dose pramipexole in the management of restless legs syndrome. An open label trial.” Neuropsychobiology, 50(1):65-70 (2004) (Abstract only)”.
[cited by applicant]
Surmeier , et al., ““Coordinated expression of dopamine receptors in neostriatal medium spiny neurons” The Journal of Neuroscience, 16(20):6579-6591 (1996)”.
[cited by applicant]
Thorpe , et al., ““Possible sites of therapeutic action in Restless Legs Syndrome: Focus on dopamine and [alpha]2 [delta] ligands” European Neurology, 66(1):18-29 (2011)”.
[cited by applicant]
Trenkwalder , et al., ““Restless legs syndrome: pathophysiology, clinical presentation and management” Nature Reviews Neurology, 6(6):337-346 (2010) (Abstract only)”.
[cited by applicant]
Trenkwalder , et al., ““The restless legs syndrome” Lancet Neurology, 4(8):465-475 (2005) (Abstract only)”.
[cited by applicant]
Trotti , et al., ““Restless legs syndrome” Handbook of Clinical Neurology, 100:661-673 (2011) (Abstract Only)”.
[cited by applicant]
Westrich , et al., ““Development of tolerance in D3 dopamine receptor signaling is accompanied by distinct changes in receptor conformation” Biochemical Pharmacology 79:897-907 (2010)”.
[cited by applicant]
Winkelmann , et al., ““Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1” PLoS Genetics, 7(7):e1002171 (2011)”.
[cited by applicant]
Winkelmann , et al., ““Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions” Nature Genetics, 39(8):1000-1006 (2007) (Abstract only)”.
[cited by applicant]
Winkelmann , et al., ““Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients” Sleep Medicine, 2(1):57-61 (2001) (Abstract only)”.
[cited by applicant]
Winkelmann , et al., ““Sensory symptoms in restless legs syndrome: the enigma of pain” Sleep Medicine, 14(10):934-942 (2013) (Abstract only)”.
[cited by applicant]
Xiong , et al., ““Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 144B(7):911-917 (2007) …
[cited by applicant]
Xu , et al., ““Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses” Cell, 79(4):729-742 (1994)”.
[cited by applicant]
Xu , et al., ““Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice” Cell, 79(6):945-955 (1994) (Abstract only)”.
[cited by applicant]
Zeng , et al., ““D3 Dopamine Receptor Directly Interacts With D1 Dopamine Receptor in Immortalized Renal Proximal Tubule Cells” Hypertension 47(part 2):573-579 (2006)”.
[cited by applicant]
Zhu , et al., ““Expression and distribution of all dopamine receptor subtypes (D1-D5) in the mouse lumbar spinal cord: A real-time polymerase chain reaction and non-autoradiographic in situ hybridization study” Neurosci…
[cited by applicant]
Zhu , et al., ““Unaltered D1, D2, D4, and D5 dopamine receptor mRNA expression and distribution in the spinal cord of the D3 receptor knockout mouse” Journal of Comparative Physiology A: Neuroethology, Sensory, Neural, …
[cited by applicant]
“Examination Report corresponding to European Application No. 16837850.3 dated Apr. 6, 2021”.
[cited by applicant]
“Summons to attend oral proceedings corresponding to European Application No. 16837850.3 dated Sep. 2, 2022”.
[cited by applicant]
Cited By (1)